Nu-Med Plus (NUMD) Return on Capital Employed (2013 - 2025)

Nu-Med Plus has disclosed Return on Capital Employed across 13 years of filings, most recently posting 17.95% for Q4 2025.

• Return on Capital Employed for Q4 2025 came in at 17.95%, down 1132.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 17.95% (down 1132.0% YoY), and the FY2025 annual result was 18.09%, down 1163.0% from the prior year.
• Return on Capital Employed came in at 17.95% for Q4 2025 at Nu-Med Plus, down from 18.86% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 2413.52% in Q3 2021 to a low of 1624.23% in Q2 2021.
• The 5-year median for Return on Capital Employed is 63.99% (2023), against an average of 114.96%.
• Across the five-year window, Return on Capital Employed jumped 601165 bps in 2021 and plunged 230581 bps in 2022, its largest moves.
• Nu-Med Plus' Return on Capital Employed stood at 712.47% in 2021, then tumbled by 75 bps to 179.98% in 2022, then plunged by 54 bps to 82.21% in 2023, then sank by 64 bps to 29.27% in 2024, then plunged by 39 bps to 17.95% in 2025.
• The last three Return on Capital Employed figures came in at 17.95% (Q4 2025), 18.86% (Q3 2025), and 22.49% (Q2 2025), per Business Quant data.